ERBB2 and ovarian carcinoma: In a meta-analysis of HER2 expression in ovarian cancer, which included 34 studies with 5180 patients, HER2 expression correlated negatively with progression-free survival (PFS), disease-free survival, and overall survival (OS) [14].